Nektar Therapeutics Balance Sheet - Quarterly (NASDAQ:NKTR)

Add to My Stocks
$18.79 $0.6 (3.09%) NKTR stock closing price Apr 26, 2017 (Closing)

The fundamental analysis of this company requires a thorough look at Nektar Therapeutics balance sheet. A balance sheet can help evaluate the financial performance of a company. Ratios like return on total assets and current ratio, which also uses cash on hand can be used to measure the operating efficiency of a firm, and can be used to conduct a more accurate Nektar Therapeutics stock analysis. Quarterly results are typically accompanied with the company releasing financial statements. Nektar Therapeutics revenue was $37.45M and Nektar Therapeutics operating cash flow was $-117.02M for 2016-Q4. The balance sheet shows total liabilities of $480.74M and shareholders equity of $88.12M. View Nektar Therapeutics quarterly results to get the balance sheet details for the latest & last 40 quarters data..

show more
Annual
Quarterly
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3
Cash59.64M63.29M55.67M72.54M55.57M18.81M45.87M154.45M37.36M57M
Marketable Securities329.46M190.21M219.17M215.77M253.37M249M233.78M171.35M225.45M204.63M
Receivables15.67M14.24M27.77M39.67M19.94M2.96M3.68M2.88M3.6M46.07M
Inventory11.1M10.75M10.26M11.25M11.34M10.35M10.12M12.51M12.95M11.69M
Raw Materials2.05M2.38M2.63M3.05M3.23M1.77M2.39M2.4M2.2M1.72M
Work In Progress7.31M6.69M6.63M7.44M6.08M8.49M6.11M7.66M5.18M8.31M
Finished Goods1.74M1.67M1M0.75M2.02M0.08M1.61M2.44M5.56M1.65M
Notes Receivable----------
Other Current Assets10.36M4M5.42M5.59M9.81M5.21M8.78M6.09M8.81M4.7M
Nektar Therapeutics Total Current Assets
426.25M282.52M318.32M344.84M350.05M286.35M302.24M347.29M288.2M324.12M
Property Plant & Equipment176.84M---174.04M---164.17M-
Accumulated Depreciation111.24M---102.71M---93.8M-
Nektar Therapeutics Net Property Plant & Equipment
65.6M65.55M67.77M69.85M71.33M72.53M72.15M69.26M70.36M69.27M
Investment & Advances----------
Other Non-Current Assets----------
Deferred Charges----------
Intangibles76.5M76.5M76.5M76.5M76.5M76.5M76.5M76.5M76.5M76.5M
Deposits & Other Assets0.51M0.51M0.5M0.68M4.17M13.86M5.76M6.15M6.55M7M
Nektar Therapeutics Total Assets
568.87M425.09M463.09M491.87M502.06M449.24M456.66M499.21M441.62M476.9M
Notes Payable----------
Accounts Payable2.81M7.11M2.32M2.34M2.36M2.27M2.83M5.02M2.7M5.42M
Current Portion Long-Term Debt-----125M----
Current Portion Capital Leases2.9M2.37M3.61M4.78M4.75M5.88M5.64M5.41M4.51M-
Accrued Expenses35.14M37.63M36.99M31.06M22.57M43.63M36.4M29.51M26.79M34.32M
Income Taxes Payable----------
Other Current Liabilities31.35M29.17M36.34M27.74M31.55M31.3M36.2M35.49M30.04M40.79M
Nektar Therapeutics Total Current Liabilities
72.22M76.3M79.28M65.94M61.24M208.09M81.07M75.44M64.04M80.54M
Mortgages----------
Deferred Taxes/Income51.88M57.08M60.13M59.58M62.42M68.94M73.96M78.41M76.91M82.9M
Convertible Debt----------
Long-Term Debt243.46M243M242.56M242.13M242.11M-125M125M125M125M
Non-Current Capital Leases2.22M2.14M2.75M3.32M1.07M1.33M2.88M4.38M4.13M5.33M
Other Long-Term Liabilities110.95M114.4M117.61M121.16M128.77M131.81M138.63M138.65M135.19M135.89M
Nektar Therapeutics Total Liabilities
480.74M492.94M502.35M492.15M495.63M410.19M421.56M421.9M405.28M429.68M
Minority Interest----------
Preferred Stock----------
Common Stock Net0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M
Capital Surplus2.11B1.91B1.9B1.89B1.88B1.85B1.84B1.83B1.82B1.79B
Retained Earnings-2.02B-1.98B-1.94B-1.89B-1.87B-1.81B-1.81B-1.75B-1.79B-1.74B
Treasury Stock----------
Other Liabilities-2.36M-1.96M-2.01M-1.83M-2.17M-1.82M-1.49M-1.27M-1.56M-1.17M
Nektar Therapeutics Shareholders Equity
88.12M-67.85M-39.25M-0.27M6.42M39.05M35.09M77.3M36.33M47.21M
Nektar Therapeutics Total Liabilities & Shareholders Equity
568.87M425.09M463.09M491.87M502.06M449.24M456.66M499.21M441.62M476.9M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Balance sheet for another ticker

1:22
NKTR
Looking at Nektar Therapeutics historical stock prices and the current Nektar Therapeutics stock price can tell you how the stock price has moved, whereas the Nektar Therapeutics PE ratio chart shows if its shares are overpriced in comparison to peers. The important things to look for in a balance sheet are:
  • Assets: An asset is a resource that a corporation like Nektar Therapeutics owns and has economic value. The two major types of assets are: fixed assets like real estate, plant and machinery and current assets like cash, marketable securities and inventory. The total asset value for NKTR stock as of quarter is $568.87M. Its easy to associate the term with manufacturing companies, which invest a lot in factories and equipment. However, the same cannot be said about tech stocks.
  • Liabilities: The total liabilities of Nektar Therapeutics for 2016-Q4 total to $480.74M. Liabilities for a company like Nektar Therapeutics include bank loans, services which have been availed for which a settlement in the form of cash/ asset transfer needs to be done in future etc. A firm takes on such obligations to grow its business which in turn will generate future economic benefits for its business.
.

Nektar Therapeutics Balance Sheet - Key Ratios

Current ratio
5.9
Debt to Equity ratio
2.82
Asset Turnover
ratio
0.3
receivables turnover
ratio
7.05
PB ratio (
price to book ratio
)
-1091.5920